Why is $LBRX moving today? · SEC 8-K archive

$LBRX SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $LBRX: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $LBRX filing catalyst

Why did $LBRX trigger an AI stock catalyst alert?

$LBRX triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -1.0/10). Headline: LB Pharmaceuticals Reports Q3 Net Loss of $59.1M, Cash Runway Extended Beyond Q2 2029. Key points: - Q3 net loss increased to $59.1M ($1.79 per share) compared to $3.6M ($0.61 per share) in Q3 2025, driven by R&D expansion. - Cash, equivalents, and investments totaled $403.8M as of September 30, 2026, funding operations beyond Q2 2029. - Phase 3 NOVA-2 topline readout for LB-102 remains on track for the first half of 2027.

How did $LBRX stock react after the SEC filing?

After the SEC 8-K for $LBRX, observed market reaction: T0 price $38.09. Past moves do not guarantee future results.

Where can I get real-time $LBRX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $LBRX via Telegram and the VIP Web Terminal from €10/month.

$LBRX

$LBRX – LB Pharmaceuticals Reports Q3 Net Loss of $59.1M, Cash Runway Extended Beyond Q2 2029

LB PHARMACEUTICALS INC

2026-11-05 00:00:00 UTC · SEC 8-K · All $LBRX

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (-1.0 / 10)

Q3 net loss increased to $59.1M ($1.79 per share) compared to $3.6M ($0.61 per share) in Q3 2025, driven by R&D expansion.
Cash, equivalents, and investments totaled $403.8M as of September 30, 2026, funding operations beyond Q2 2029.
Phase 3 NOVA-2 topline readout for LB-102 remains on track for the first half of 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →